Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Dimebon alone Clear all

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hepatic Failure
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Orlando, Florida • Indianapolis, Indiana

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon IR, Dimebon Transdermal; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Miami, Florida • Saint Paul, Minnesota

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Alzheimer's Disease, Huntington Disease
Interventions: Dimebon IR Tablet, Dimebon MR1, Dimebon MR2, Dimebon MR3, Dimebon MR4; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Huntington Disease, Alzheimer Disease
Interventions: Dextromethorphan, Dimebon + Dextromethorphan; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Warfarin, Dimebon; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [Pf-01913539] In Subjects With Hepatic Impairment And Normal Hepatic Function

A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan

A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects